Menu
Search
|

Menu

Close
X

Aratana Therapeutics Inc PETX.OQ (NASDAQ Stock Exchange Global Market)

3.90 USD
+0.09 (+2.36%)
As of 4:00 PM EDT
chart
Previous Close 3.81
Open 3.82
Volume 61,015
3m Avg Volume 111,373
Today’s High 3.93
Today’s Low 3.77
52 Week High 7.16
52 Week Low 3.31
Shares Outstanding (mil) 48.97
Market Capitalization (mil) 186.59
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
35
FY17
26
FY16
39
EPS (USD)
FY18
-0.322
FY17
-1.179
FY16
-0.932
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
41.05
Price to Sales (TTM)
vs sector
5.27
8.91
Price to Book (MRQ)
vs sector
1.82
4.65
Price to Cash Flow (TTM)
vs sector
--
28.95
Total Debt to Equity (MRQ)
vs sector
0.00
17.48
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-14.68
12.19
Return on Equity (TTM)
vs sector
-16.27
13.29

EXECUTIVE LEADERSHIP

Wendy Yarno
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Craig Tooman
President, Chief Executive Officer, Director, Since 2019
Salary: $350,000.00
Bonus: --
Rhonda Hellums
Chief Financial Officer, Treasurer, Since 2019
Salary: --
Bonus: --
Ernst Heinen
Chief Development Officer, Since 2014
Salary: $302,500.00
Bonus: --
Craig Barbarosh
Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11400 Tomahawk Creek Pkwy Ste 34
LEAWOOD   KS   66211-2730

Phone: +1913.3531000

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

SPONSORED STORIES